1. Home
  2. JLL vs RDY Comparison

JLL vs RDY Comparison

Compare JLL & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jones Lang LaSalle Incorporated

JLL

Jones Lang LaSalle Incorporated

HOLD

Current Price

$284.74

Market Cap

13.5B

Sector

Finance

ML Signal

HOLD

Logo Dr. Reddy's Laboratories Ltd

RDY

Dr. Reddy's Laboratories Ltd

HOLD

Current Price

$13.64

Market Cap

11.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JLL
RDY
Founded
1997
1984
Country
United States
India
Employees
48000
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.5B
11.6B
IPO Year
1997
2001

Fundamental Metrics

Financial Performance
Metric
JLL
RDY
Price
$284.74
$13.64
Analyst Decision
Buy
Strong Buy
Analyst Count
7
1
Target Price
$365.33
$16.90
AVG Volume (30 Days)
354.0K
2.5M
Earning Date
04-30-2026
05-12-2026
Dividend Yield
N/A
0.52%
EPS Growth
45.13
N/A
EPS
3.33
N/A
Revenue
$26,115,600,000.00
N/A
Revenue This Year
$7.71
$7.72
Revenue Next Year
$6.99
$3.50
P/E Ratio
$85.49
$18.67
Revenue Growth
11.45
N/A
52 Week Low
$217.21
$12.19
52 Week High
$363.06
$16.17

Technical Indicators

Market Signals
Indicator
JLL
RDY
Relative Strength Index (RSI) 31.74 53.17
Support Level $278.44 $12.90
Resistance Level $309.79 $13.99
Average True Range (ATR) 10.47 0.23
MACD -1.64 0.03
Stochastic Oscillator 17.98 84.80

Price Performance

Historical Comparison
JLL
RDY

About JLL Jones Lang LaSalle Incorporated

Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $86 billion for clients across diverse public and private real estate strategies as of the end of 2025.

About RDY Dr. Reddy's Laboratories Ltd

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Share on Social Networks: